AC
Amia Capital Portfolio holdings
AUM
$32.1M
This Quarter Return
+13.17%
1 Year Return
-3.89%
3 Year Return
+25.64%
5 Year Return
–
10 Year Return
–
AUM
$343M
AUM Growth
–
Cap. Flow
+$343M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
88.26%
Holding
41
New
41
Increased
–
Reduced
–
Closed
–
Top Buys
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 26.19% |
| 2 | Energy | 3.72% |
| 3 | Communication Services | 3.4% |
| 4 | Materials | 3.08% |
| 5 | Consumer Discretionary | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MYOK
26
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $992K | 0.29% |
+13,616
| New | +$992K |
|
|
ICPT
27
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $951K | 0.28% |
+7,678
| New | +$951K |
|
|
BOLD
28
DELISTED
Audentes Therapeutics, Inc
BOLD
| $910K | 0.27% |
+15,205
| New | +$910K |
|
|
MYOV
29
DELISTED
Myovant Sciences Ltd.
MYOV
| $830K | 0.24% |
+53,508
| New | +$830K |
|
30
Nektar Therapeutics
NKTR
$541M
| $583K | 0.17% |
+27,028
| New | +$583K |
|
31
Exelixis
EXEL
$9.96B
| $530K | 0.15% |
+30,096
| New | +$530K |
|
32
CRISPR Therapeutics
CRSP
$4.82B
| $513K | 0.15% |
+8,427
| New | +$513K |
|
33
MacroGenics
MGNX
$121M
| $486K | 0.14% |
+44,648
| New | +$486K |
|
|
AKCA
34
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $478K | 0.14% |
+28,217
| New | +$478K |
|
35
Q32 Bio
QTTB
$20.7M
| $426K | 0.12% |
+20,597
| New | +$426K |
|
36
UBS Group
UBS
$126B
| $325K | 0.09% |
+25,840
| New | +$325K |
|
37
Sangamo Therapeutics
SGMO
$160M
| $311K | 0.09% |
+37,112
| New | +$311K |
|
38
Gilead Sciences
GILD
$140B
| $308K | 0.09% |
+4,746
| New | +$308K |
|
39
Bristol-Myers Squibb
BMY
$96.6B
| $277K | 0.08% |
+4,321
| New | +$277K |
|
40
Voyager Therapeutics
VYGR
$205M
| $275K | 0.08% |
+19,683
| New | +$275K |
|
41
Wave Life Sciences
WVE
$1.25B
| $165K | 0.05% |
+20,646
| New | +$165K |
|